MOSCOW, Feb. 5, 2014 /PRNewswire/ -- On February 3, 2014, ZAO Rafarma management met with
senior faculty members of the St. Petersburg Academy of
Pharmaceutical Chemistry to create a long-term cooperative
agreement.
Rafarma will work with and be able to recruit from the finest
pharmaceutical specialists graduating in Russia, as well as having access to the
Academy's innovative pharmaceutical research.
The cooperative agreement is borne out of the initiatives
outlined in "Pharma 2020," the Russian National Pharmaceutical
Strategy. For the Academy, the agreement creates specialized and
tailored educational programs allowing undergraduates exposure to
Rafarma's most innovative testing protocols at Rafarma's
state-of-the-art facilities under highly-skilled technical
supervision.
"Such cooperative agreements with pharmaceutical higher
education continue to raise Rafarma's leadership position in the
Russian pharmaceutical industry. We are delighted to have an
institution of such extraordinary reputation as a partner,"
commented Rafarma's CEO David
Anderson.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art
manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces
generic antibiotics and specialty pharmaceuticals in addition to
its own line of proprietary products that are approved by the
Ministry of Health of Russian
Federation. For the last three years, the Russian Government
has been highly focused on bolstering the development of the
nation's domestic pharmaceutical industry. Rafarma's mission is to
work under the auspices of these aggressive federal initiatives to
fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit:
http://rafarma.com
About The St. Petersburg Academy of Pharmaceutical Chemistry
A center of academic excellence, the St. Petersburg Academy of
Pharmaceutical Chemistry was established 90 years ago and is
currently the most prestigious higher education facility in
Russia. With over 175 faculty
members the Academy has more than 3,000 students studying 57
different subjects; producing the most highly-qualified specialists
for the Russian pharmaceutical industry. The graduates of the
Academy are citizens of more than 40 countries of Europe, Asia,
Africa and Latin America. The Academy is the winner of
international prize "Profession is Life" in the category "Best
medical school," has a Gold Medal "European Quality" in the
nomination "100 Best Universities of Russia" (2004, 2005, 2009) and Gold Medal "Top
100 in Russia in Science and
Education" (2010).
Safe Harbor Statement
Matters discussed in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend," "expect" and
similar expressions identify such forward-looking statements.
Actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the
forward-looking statements contained herein. These forward-looking
statements are based largely on the expectations of the Company and
are subject to a number of risks and uncertainties. These include,
but are not limited to: the impact of economic, competitive and
other factors affecting the Company and its operations, markets,
product, and distributor performance.
RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo
RELATED LINKS
http://rafarma.com
SOURCE Rafarma Pharmaceuticals, Inc.